Sundry Photography/iStock Editorial via Getty Images By Nicholas Tan, Investment Research Analyst @ Khaveen Investments In our previous analysis of HPE ( HPE ), we expected the company to sustain market share in both enterprise network infrastructure and external OEM storage. We further expected the company to achieve margin expansion. Company Data, Khaveen Investments Since our last coverage, HPE...
Sundry Photography/iStock Editorial via Getty Images By Nicholas Tan, Investment Research Analyst @ Khaveen Investments In our previous analysis of HPE ( HPE ), we expected the company to sustain market share in both enterprise network infrastructure and external OEM storage. We further expected the company to achieve margin expansion. Company Data, Khaveen Investments Since our last coverage, HPE acquired Juniper Networks for $14 billion in July 2025 . To acquire Juniper Networks, HPE raised $8.99 billion of debt in September 2024 and $ 2.9 billion of debt in September 2025, respectively. As such, HPE’s debt rose from $13.0 billion in 2023 to $23.4 billion in 2025. Due to higher debt and the completion of Juniper’s acquisition in 2025, we can see that Net Debt to EBITDA rose from 2.03x in 2023 to 4.09x in 2025, which is much higher than its historical 10-year average of 1.98x. We also find that the Net Debt decline in 2024 was mainly because HPE sold 30% of its stake in H3C to UNIS for $2.1 billion and also issued $1.35 billion of mandatory convertible preferred stock to raise cash for the acquisition. Currently, management plans to achieve a 2.0x net debt to EBITDA target by FY2027. In this analysis, we thus analyze whether HPE can achieve this target. We first evaluate whether its EBITDA can continue to grow, and further assess whether its EBITDA margins can continue to improve. We lastly analyze whether it can reduce its Net Debt. EBITDA To Climb Higher Company Data, Khaveen Investments To analyze whether HPE’s EBITDA can continue to grow, we thus compile its historical EBITDA and revenue breakdown. We find that EBITDA grew with an average of 0.54%, while revenue grew with an average of 1.59%. We also see that Networking grew the fastest among its segments (25.05%), while Server, its largest segment, grew only 5.75% on average. According to IDC , the Server market grew with an average growth of 57.39% over the last 3 years, which is much higher than HPE’s growth...
hapabapa/iStock Editorial via Getty Images Novo Nordisk ( NVO ) recorded a 40% rise in sales in India for its GLP-1 medicine, semaglutide, last month, following sharp price cuts that boosted demand despite a wave of generics, Bloomberg reported on Friday, citing market researcher Pharmarack. In March, the Danish drugmaker lost exclusivity for its core patent for semaglutide, marketed as Ozempic an...
hapabapa/iStock Editorial via Getty Images Novo Nordisk ( NVO ) recorded a 40% rise in sales in India for its GLP-1 medicine, semaglutide, last month, following sharp price cuts that boosted demand despite a wave of generics, Bloomberg reported on Friday, citing market researcher Pharmarack. In March, the Danish drugmaker lost exclusivity for its core patent for semaglutide, marketed as Ozempic and Wegovy, in India, paving the way for low-cost biosimilar versions in the world’s most populous country, where obesity rates are rapidly rising. According to Pharmarack data, sales of Wegovy, Ozempic, and partner-branded versions of the GLP-1 climbed to 32,000 units in April, the first full month since the launch of semaglutide generics. The company slashed the prices of starting doses of Wegovy and Ozempic to ₹5,660 ($60) effective April 1, indicating a 36% and 48% decline, respectively, to fend off competition from low-cost versions manufactured by local rivals. Meanwhile, the overall GLP-1 market in India is fast expanding amid a surge in demand for knockoff versions that can cost as low as $14 for a monthly dose. The market expanded to 414,000 units in April, indicating a 56% rise from the prior month, while Eli Lilly ( LLY ) maintained its leadership position as the number one GLP-1 provider. “So far, generics have led to the expansion of the market over a significant erosion of market share from innovators,” said Sheetal Sapale, vice president of commercial at Pharmarack. India could be a test case for how well off-patent versions can erode demand for branded GLP-1 therapies, as the South Asian country was the first market where Novo ( NVO ) faced generic competition against its best-selling product. Earlier this year, the company projected its 2026 profit to decline 5% YoY–13% YoY on a forex-adjusted basis due to the patent expiry of semaglutide and its drug-pricing agreement with the Trump administration. More on Novo Nordisk A/S Novo Nordisk: Mixed Q1 Does Not Bre...
Roman Tiraspolsky/iStock Editorial via Getty Images Introduction The last time I covered NNN REIT ( NNN ), I highlighted their attractive valuation, solid performance, and decent growth expectations even during a tough environment, navigating the macro headwinds well. Following a solid first quarter and a slight boost in their AFFO guidance, NNN remains a Buy, with a valuation that already implies...
Roman Tiraspolsky/iStock Editorial via Getty Images Introduction The last time I covered NNN REIT ( NNN ), I highlighted their attractive valuation, solid performance, and decent growth expectations even during a tough environment, navigating the macro headwinds well. Following a solid first quarter and a slight boost in their AFFO guidance, NNN remains a Buy, with a valuation that already implies a solid margin of safety given the Iran pressure, while the dividend remains attractive and very sustainable. Solid Quarter Despite Pressure NNN REIT IR NNN reported a good first quarter overall, with FFO in line with the market's expectations and a slight beat on revenue, with the AFFO reaching $165.68 million (vs. $163.02 million last year), or about $0.87 per share, with the occupancy rate further improving to 98.6%, adding 41 new properties for $145.39 million, with a solid weighted average cap rate of 7.5% and a very strong 19-year weighted average lease term on these new properties—also disposing of 25 properties (16 of which were vacant). NNN REIT IR NNN also announced hiking its guidance for 2026, boosting the AFFO estimate by one cent to $3.53 to $3.59 per share, while keeping the acquisition and disposition volume at the same $550 million to $650 million and $110 million to $150 million, respectively. As we can see from the size of the recent deals, the company continues to take advantage of what they call “granular opportunities,” with very few transactions above $50 million, focusing instead on those between $5 million and $50 million or even below $5 million, which is an advantage that larger peers don't have, as they are forced into major deals if they want something that would move the needle, potentially sacrificing cap rates as a result. NNN REIT IR Financially, based on NNN’s latest report , we continue to see a regular position for a REIT, with limited cash available and their significant assets being enough to cover the total debt even when taking into ...
Shares of The Trade Desk (NASDAQ:TTD) are down roughly 13% to $20.41 in early Friday trading after the company posted a Q1 2026 earnings miss and issued a softer Q2 2026 outlook than the Street had hoped to see. The stock closed Thursday at $23.49, already down 38% year to date (YTD) heading into the ... Trade Desk Tumbles 13%, AppLovin Holds Gains as Ad-Tech Q1 Earnings Split Wall Street
Shares of The Trade Desk (NASDAQ:TTD) are down roughly 13% to $20.41 in early Friday trading after the company posted a Q1 2026 earnings miss and issued a softer Q2 2026 outlook than the Street had hoped to see. The stock closed Thursday at $23.49, already down 38% year to date (YTD) heading into the ... Trade Desk Tumbles 13%, AppLovin Holds Gains as Ad-Tech Q1 Earnings Split Wall Street
BioAge Labs press release ( BIOA ): Q1 GAAP EPS of -$0.52. Revenue of $2.8M. As of March 31, 2026, BioAge had approximately $384.9 million in cash, cash equivalents, and marketable securities. Based on its current operating plan, BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029. More on BioAge Labs BioAge Labs, Inc. (B...
BioAge Labs press release ( BIOA ): Q1 GAAP EPS of -$0.52. Revenue of $2.8M. As of March 31, 2026, BioAge had approximately $384.9 million in cash, cash equivalents, and marketable securities. Based on its current operating plan, BioAge estimates that existing cash and cash equivalents will be sufficient to fund operations and capital expenses through 2029. More on BioAge Labs BioAge Labs, Inc. (BIOA) Discusses Phase I Results and Development Plans for BGE-102 NLRP3 Inhibitor Transcript BioAge Labs: Oral NLRP3 Inhibitor Could Establish PoC In CV This Year BioAge Labs GAAP EPS of -$2.24 beats by $0.08, revenue of $8.99M beats by $1.88M Small-Cap healthcare stocks ranked by quant ratings after earnings season Seeking Alpha’s Quant Rating on BioAge Labs
(RTTNews) - Madison Square Garden Sports Corp. (MSGS), on Friday posted a wider quarterly net loss even as revenue rose, driven by a sharp drop in operating income.
(RTTNews) - Madison Square Garden Sports Corp. (MSGS), on Friday posted a wider quarterly net loss even as revenue rose, driven by a sharp drop in operating income.
Despite a year-to-date decline, Palantir continues to deliver accelerating U.S. commercial growth, strong cash flow, and high-profile partnerships, prompting analysts and investors to debate whether PLTR stock deserves its premium valuation.
Despite a year-to-date decline, Palantir continues to deliver accelerating U.S. commercial growth, strong cash flow, and high-profile partnerships, prompting analysts and investors to debate whether PLTR stock deserves its premium valuation.
sasha85ru/iStock via Getty Images Since July 2025, I have maintained a clear buy rating on Trinity Capital Inc. ( TRIN ) and issued numerous follow-up pieces suggesting investors keep holding (and adding) to this BDC darling despite its gains. And this is how Trinity Capital has performed since then: YCharts It has not only outperformed the BDC index, as proxied by the VanEck BDC Income ETF ( BIZD...
sasha85ru/iStock via Getty Images Since July 2025, I have maintained a clear buy rating on Trinity Capital Inc. ( TRIN ) and issued numerous follow-up pieces suggesting investors keep holding (and adding) to this BDC darling despite its gains. And this is how Trinity Capital has performed since then: YCharts It has not only outperformed the BDC index, as proxied by the VanEck BDC Income ETF ( BIZD ), but also delivered positive results this year when the overall space has sold off mostly due to fears about mounting SaaS defaults. My thesis of valuation convergence between TRIN and other high-quality internally managed BDC peers — Main Street Capital Corporation ( MAIN ), Hercules Capital, Inc. ( HTGC ) and Capital Southwest ( CSWC ) — has been working out nicely. YCharts The convergence has played out on all fronts: Hercules and Main Street experiencing P/NAV compression. Capital Southwest is appreciating but at a slower pace than Trinity. Trinity is going gangbusters. Of course, the final bullet is the most important one and what should really matter for us, long-term investors. Just recently, Trinity circulated its Q1 2026 earnings results which were strong across the board. However, some after seeing such a huge divergence between Trinity's P/NAV movement and that of most other BDC peers might start to wonder whether Trinity has any upside left. I will try to answer this and update my thesis based on Q1 data points. Thesis Review I don't want to spoil something here but by digesting the results and commentary by the Management I don't see how TRIN could leave my Top 3 BDC spot any time soon. As some of my followers have noticed, the other two Top 3 picks are CSWC and Kayne Anderson BDC, Inc. ( KBDC ). In Q1, Trinity registered NII per share growth which is a notable fact in itself. For the context, the lion's share of BDC peers have reported contracting NII per share levels so far. This includes such names as Sixth Street Specialty Lending, Inc. ( TSLX ), Golub C...
IP Strategy Holdings， Inc．宣布，由Poseidon开发的消费者应用程序Numo已上线抢先体验版。该应用旨在通过授权收集真实世界数据，扩大人工智能（AI）系统训练数据集规模，以应对行业日益增长的高质量数据需求。 当前，人工智能行业的数据需求正面临供应瓶颈。新一代AI系统的研发高度依赖反映人类真实言语、行为与互动的数据，此类高质量数据难以从开放互联网直接获取。针对这一行业痛点...
IP Strategy Holdings， Inc．宣布，由Poseidon开发的消费者应用程序Numo已上线抢先体验版。该应用旨在通过授权收集真实世界数据，扩大人工智能（AI）系统训练数据集规模，以应对行业日益增长的高质量数据需求。 当前，人工智能行业的数据需求正面临供应瓶颈。新一代AI系统的研发高度依赖反映人类真实言语、行为与互动的数据，此类高质量数据难以从开放互联网直接获取。针对这一行业痛点，Numo应用允许用户通过移动设备完成简单任务以贡献数据，初期项目重点聚焦于代表性不足语言的语音采集。 在合规性与可追溯性方面，相关数据一经提交，即通过Story平台进行来源核实与权利厘清，并依托链上授权机制，确保数据集具备即时商业应用价值与透明溯源能力。此举有效规避了AI系统在实际生产应用中的所有权与合规争议。初步市场数据显示，Numo平台上线首周已吸引逾1.5万名贡献者参与，生成四种语言共计17万余条语音录制。随着参与度持续上升，该应用预计将于近期引入更多语种及数据收集任务。 针对该项目的行业前景，IP Strategy Holdings指出，Numo的发布有效证明了真实世界数据能够转化为可扩展且权利明晰的资产类别，从而为下一代AI系统提供具备商业用途的训练基础。该公司强调，未来将继续重点推动相关生态系统的建设，扩大高价值数据的市场供应，支持合规化人工智能系统的发展，并促进可编程知识产权基础设施的长期应用。 责任编辑：龙运翔
Turkey’s wheat harvest is poised for a sharp recovery from last year’s crop-ravaging droughts, potentially curbing the outlook for imports from one of the world’s largest wheat buyers. Output may rise about 20% to roughly 22 million tons in 2026, according to officials familiar with preliminary assessments, who asked not to be identified because the forecasts haven’t been released yet by the gover...
Turkey’s wheat harvest is poised for a sharp recovery from last year’s crop-ravaging droughts, potentially curbing the outlook for imports from one of the world’s largest wheat buyers. Output may rise about 20% to roughly 22 million tons in 2026, according to officials familiar with preliminary assessments, who asked not to be identified because the forecasts haven’t been released yet by the government. That would bring production close to a record 22.6 million tons seen in 2015. The agriculture ministry declined to comment. Turkey is among the world’s largest wheat importers and much of the grain is used to supply its vast flour-milling industry. Higher domestic wheat output may reduce import needs in the upcoming season. The rebound follows one of Turkey’s driest years in decades, which battered agricultural output across the country and contributed to an 8.8% contraction in the farming sector last year, even as the broader economy expanded 3.6%. Improved rainfall across key farming regions, including central Anatolia, has boosted expectations for this season’s harvest. Speaking last month in Konya, Turkey’s main grain-producing province, Agriculture Minister Ibrahim Yumakli said the crop would more than make up for losses suffered a year earlier. He also said the government would continue supporting farmers through procurement prices, according to state-run Anadolu Agency. The government is due to publish its first official crop estimates for the season on June 3.